date of ta availability of medicine for nhs patients with ... · constipation (ta345) jul-15...

NICE Technology Appraisals About Medicines: Formulary Adherence Checklist

2015-2016 City and Hackney Clinical Commissioning Group

Homerton University Hospital Foundation Trust

Technology appraisal (TA) Titles are hyperlinks to full guidance

Date of TA

Release

Availability of medicine for NHS patients with this

medical condition, as indicated by NICEDate of local

decision

(DD/MM/YY)

2015-16

TA340

Ustekinumab for treating active psoriatic

arthritis (rapid review of technology

appraisal guidance 313) (TA340)

Jun-15

Ustekinumab (Stelara) is recommended as a possible

treatment, alone or with a drug called methotrexate, for

adults with active psoriatic arthritis when treatment with non-

biological disease-modifying antirheumatic drugs (or

DMARDS) has not worked well enough if:

l• treatment with tumour necrosis factor (TNF) alpha

inhibitors is not suitable for them, or

l• the person has had a TNF alpha inhibitor before.

Treatment with ustekinumab should be stopped after 24

weeks if it is not working well enough.

Jun-15

TA341

Apixaban for the treatment and

secondary prevention of deep vein

thrombosis and/or pulmonary embolism

(TA341)

Jun-15

Apixaban is recommended, within its marketing

authorisation, as an option for treating and for preventing

recurrent deep vein thrombosis and pulmonary embolism in

adults.

Jun-15

TA342Vedolizumab for treating moderately to

severely active ulcerative colitis (TA342)Jun-15

Vedolizumab is recommended, within its marketing

authorisation, as an option for treating moderately to

severely active ulcerative colitis in adults only if the

company provides vedolizumab with the discount agreed in

the patient access scheme.

Vedolizumab should be given until it stops working or

surgery is needed. At 12 months after the start of

treatment, people should be reassessed to see whether

treatment should continue. Treatment should only continue

if there is clear evidence of ongoing clinical benefit. For

people in complete remission at 12 months, consider

stopping vedolizumab, resuming treatment if there is a

relapse. People who continue vedolizumab should be

reassessed at least every 12 months to see whether

continued treatment is justified.

Jun-15

Adherence of local formulary to NICE

Developed for the NHS by NHS East and South East Specialist Pharmacy Services 1 of 36

http://www.nice.org.uk/guidance/ta340












TA343

Obinutuzumab in combination with

chlorambucil for untreated chronic

lymphocytic leukaemia (TA343)

Jun-15

Obinutuzumab, in combination with chlorambucil, is

recommended as an option for adults with untreated

chronic lymphocytic leukaemia who have comorbidities that

make full‑dose fludarabine‑based therapy unsuitable for

them, only if:

• bendamustine based therapy is not suitable and

• the company provides obinutuzumab with the discount

agreed in the patient access scheme.

Jun-15

TA344

Ofatumumab in combination with

chlorambucil or bendamustine for

untreated chronic lymphocytic leukaemia

(TA344)

Jun-15

Ofatumumab (Arzerra) given with a drug called

chlorambucil is recommended as a possible treatment for

people with untreated chronic lymphocytic leukaemia if

treatments containing fludarabine or bendamustine are not

suitable.

Jun-15

TA345Naloxegol for treating opioid‑induced

constipation (TA345)Jul-15

Naloxegol is recommended, within its marketing

authorisation, as an option for treating opioid induced

constipation in adults whose constipation has not

adequately responded to laxatives.

• An inadequate response is defined as opioid induced

constipation symptoms of at least moderate severity in at

least 1 of the 4 stool symptom domains (that is, incomplete

bowel movement, hard stools, straining or false alarms)

while taking at least 1 laxative class for at least 4 days

during the prior 2 weeks

Sep-15









https://www.nice.org.uk/guidance/ta345





TA346Aflibercept for treating diabetic macular

oedema (TA346)Jul-15

Aflibercept solution for injection is recommended as an

option for treating visual impairment caused by diabetic

macular oedema only if:

• the eye has a central retinal thickness of 400 micrometres

or more at the start of treatment and

• the company provides aflibercept with the discount agreed

in the patient access scheme.

People whose treatment with aflibercept is not

recommended in this NICE guidance, but was started within

the NHS before this guidance was published, should be

able to continue aflibercept until they and their NHS

clinician consider it appropriate to stop.

Sep-15

TA347

Nintedanib for previously treated locally

advanced, metastatic, or locally recurrent

non‑small‑cell lung cancer (TA347)

Jul-15

Nintedanib in combination with docetaxel is recommended,

within its marketing authorisation, as an option for treating

locally advanced, metastatic or locally recurrent

non‑small‑cell lung cancer of adenocarcinoma histology

that has progressed after first‑line chemotherapy, only if

the company provides nintedanib with the discount agreed

in the patient access scheme.

Sep-15

TA348Everolimus for preventing organ rejection

in liver transplantation (TA348)Jul-15

Everolimus is not recommended within its marketing

authorisation for preventing organ rejection in people

having a liver transplant.

People whose treatment with everolimus was started within


able to continue everolimus until they and their NHS

clinician consider it appropriate to stop.

Sep-15












TA349

Dexamethasone intravitreal implant for

treating diabetic macular oedema

(TA349)

Jul-15

Dexamethasone intravitreal implant is recommended as an

option for treating diabetic macular oedema only if:

the implant is to be used in an eye with an intraocular

(pseudophakic) lens and

the diabetic macular oedema does not respond to

non‑corticosteroid treatment, or such treatment is

unsuitable.

People whose treatment with dexamethasone intravitreal

implant was started within the NHS before this guidance

was published, but is not recommended for them by NICE

in this guidance, should be able to continue treatment until

they and their NHS clinician consider it appropriate to stop.

Sep-15








TA350Secukinumab for treating moderate to

severe plaque psoriasis (TA350)Jul-15

Secukinumab is recommended, within its marketing

authorisation, as an option for treating adults with plaque

psoriasis only when:

• the disease is severe, as defined by a total Psoriasis Area

Severity Index (PASI) of 10 or more and a Dermatology Life

Quality Index (DLQI) of more than 10

• the disease has failed to respond to standard systemic

therapies, for example, ciclosporin, methotrexate and

PUVA (psoralen and long wave ultraviolet radiation), or

these treatments are contraindicated or the person cannot

tolerate them

• the company provides secukinumab with the discount


Secukinumab treatment should be stopped in people

whose psoriasis has not responded adequately at 12

weeks. Further treatment cycles are not recommended in

these people. An adequate response is defined as either:

• a 75% reduction in the PASI score from when treatment

started (PASI 75) or

• a 50% reduction in the PASI score (PASI 50) and a 5

point reduction in DLQI from when treatment started.

People whose treatment with secukinumab is not

recommended in this NICE guidance, but was started within


able to continue treatment until they and their NHS clinician

consider it appropriate to stop.

When using the DLQI, healthcare professionals should take

into account any physical, sensory or learning disabilities,

or communication difficulties, that could affect the

responses to the DLQI and make any adjustments they

consider appropriate.

Sep-15

TA351

Cangrelor for reducing atherothrombotic

events in people undergoing

percutaneous coronary intervention or

awaiting surgery requiring interruption of

anti‑platelet therapy (terminated

appraisal) (TA351)

Jul-15

NICE is unable to make a recommendation about the use in

the NHS of cangrelor for reducing atherothrombotic events

in people undergoing percutaneous coronary intervention

or awaiting surgery requiring interruption of anti-platelet

therapy because no evidence submission was received

from The Medicines Company.

Sep-15













TA339Omalizumab for previously treated

chronic spontaneous urticaria (TA339)Jun-15

Omalizumab (Xolair) is recommended as a possible

treatment for people aged 12 years and over with severe

chronic spontaneous urticaria if:

• a doctor has objectively diagnosed the condition as

severe

• the condition has not improved with standard treatment

with H1 antihistamines or leukotriene receptor antagonists

• the drug is stopped at or before the fourth dose if the

condition has not responded

• the drug is stopped at the end of a course of treatment (6

doses) if the condition has responded, and is only restarted

if the condition comes back

• the drug is given by a secondary care specialist in

dermatology, immunology or allergy.

Sep-15







TA352

Vedolizumab for treating moderately to

severely active Crohn's disease after

prior therapy

Aug-15

Vedolizumab is recommended as an option for treating

moderately to severely

active Crohn's disease only if:

a tumour necrosis factor-alpha inhibitor has failed (that is,

the disease has

responded inadequately or has lost response to treatment)

or

a tumour necrosis factor-alpha inhibitor cannot be tolerated

or is contraindicated.

Vedolizumab is recommended only if the company provides

it with the discount


Vedolizumab should be given as a planned course of

treatment until it stops

working or surgery is needed, or until 12 months after the

start of treatment,

whichever is shorter. At 12 months, people should be

reassessed to determine

whether treatment should continue. Treatment should only

continue if there is

clear evidence of ongoing clinical benefit. For people in

complete remission at

12 months, consider stopping vedolizumab, resuming

treatment if there is a

relapse. People who continue vedolizumab should be

reassessed at least

every 12 months to decide whether continued treatment is

justified.

Oct-15

TA353

Bevacizumab for treating relapsed,

platinum‑resistant epithelial ovarian,

fallopian tube or primary peritoneal

cancer (terminated appraisal

Aug-15


the NHS of bevacizumab for treating relapsed, platinum-

resistant epithelial ovarian, fallopian tube or primary

peritoneal cancer because no evidence submission was

received from Roche Products for the technology.

Oct-15

TA354

Edoxaban for treating and for preventing

deep vein thrombosis and pulmonary

embolism

(TA354)

Aug-15

Edoxaban (Lixiana) is recommended as an option for

treating and preventing recurrent deep vein thrombosis or

pulmonary embolism.

Oct-15
















TA355

Edoxaban for preventing stroke and

systemic embolism in people with

non‑valvular atrial fibrillation

Sep-15

Edoxaban (Lixiana) is recommended as an option for

preventing stroke and systemic embolism in people with

non-valvular atrial fibrillation who have one or more risk

factors, such as:

heart failure, high blood pressure or diabetes

had a stroke or transient ischaemic attack before

aged 75 years or older.

Oct-15

TA356Ruxolitinib for treating polycythaemia vera

(terminated appraisal)Sep-15

Ruxolitinib for treating polycythaemia vera (terminated

appraisal)Oct-15

TA358Tolvaptan for treating autosomal

dominant polycystic kidney diseaseOct-15

Tolvaptan (Jinarc) is recommended as a possible treatment

for people with autosomal dominant polycystic kidney

disease if:

they have chronic kidney disease stage 2 or 3 at the start of

treatment and

there is evidence of rapidly progressing disease.

Nov-15

TA361

Simeprevir in combination with sofosbuvir

for treating genotype 1 or 4 chronic

hepatitis C (terminated appraisal)

Oct-15

Simeprevir in combination with sofosbuvir for treating

genotype 1 or 4 chronic hepatitis C no evidence submission

was received from Janssen

Nov-15

TA357

Pembrolizumab for treating advanced

melanoma after disease progression with

ipilimumab

Oct-15

Pembrolizumab (Keytruda) is recommended. This drug is a

possible treatment for adults with melanoma that:

can’t be completely removed by surgery or has spread to

other parts of the body

has been treated with ipilimumab (melanoma that is BRAF

V600 mutation-positive must also have had treatment with

vemurafenib, dabrafenib, or trametinib).

Nov-15







https://www.nice.org.uk/guidance/TA358

https://www.nice.org.uk/guidance/TA358










TA362

Paclitaxel as albumin-bound

nanoparticles with carboplatin for

untreated non-small-cell lung cancer

(terminated appraisal)

Oct-15


the NHS of paclitaxel as albumin-bound nanoparticles with

carboplatin for adults with untreated non-small-cell lung

cancer when potentially curative surgery or radiation

therapy or both are unsuitable, because no evidence

submission was received from Celgene technology.

Nov-15

TA360

Paclitaxel as albumin-bound

nanoparticles in combination with

gemcitabine for previously untreated

metastatic pancreatic cancerOct-15

Nab-paclitaxel (Abraxane) with gemcitabine (Gemzar) is not

recommended for adults with metastatic adenocarcinoma of

the pancreas that has not been treated before. Nov-15

TA359Idelalisib for treating chronic lymphocytic

leukaemiaOct-15

Idelalisib (Zydelig), given with a drug called rituximab, is

recommended as a possible treatment for adults

with:untreated chronic lymphocytic leukaemia, only if they

have certain genetic chatacteristics chronic lymphocytic

leukaemia, only if it has been treated but has come back

within 2 years.

Nov-15

TA363

Ledipasvir–sofosbuvir for treating chronic

hepatitis C Nov-15

Ledipasvir-sofosbuvir (Harvoni) is recommended as a

possible treatment for adults with some types (called

genotypes) of chronic hepatitis C.

Jan-16

TA364 Daclatasvir for treating chronic hepatitis C Nov-15

Daclatasvir (Daklinza) is recommended as a possible

treatment for adults with some types (called genotypes) of

chronic hepatitis C, depending on their level of fibrosis. It is

taken with sofosbuvir or peginteron alfa, and sometimes

with a drug called ribavirin.

Jan-16

TA365

Ombitasvir–paritaprevir–ritonavir with or

without dasabuvir for treating chronic

hepatitis C

Nov-15

Ombitasvir–paritaprevir–ritonavir with or without dasabuvir

is recommended,

within its marketing authorisation, as an option for treating

genotype 1 or 4

chronic hepatitis C in adults, as specified in table 1, only if

the company provides

ombitasvir–paritaprevir–ritonavir and dasabuvir at the same

price or lower

than that agreed with the Commercial Medicines Unit.

Jan-16


http://www.nice.org.uk/guidance/TA362




















TA366

Pembrolizumab for advanced melanoma

not previously treated with ipilimumab Nov-15

Pembrolizumab (Keytruda) is recommended. This drug is a

possible treatment for adults with melanoma that:

can’t be completely removed by surgery or has spread to

other parts of the body

has not been treated with ipilimumab before.

Jan-16

TA367Vortioxetine for treating major depressive

episodesNov-15

Vortioxetine (Brintellix) is recommended as a possible

treatment for adults having a first or recurrent major

depressive episode, if the current episode has not

responded to 2 antidepressants.Jan-16

TA368Apremilast for treating moderate to

severe plaque psoriasisNov-15

Apremilast (Otezla) is not recommended for treating

moderate to severe chronic plaque psoriasis in adults

whose psoriasis has not improved with other treatments, or

they have had side effects with these treatments in the past

or there is a reason why they cannot have them.

Jan-16

TA369

Ciclosporin for treating dry eye disease

that has not improved despite treatment

with artificial tears

Dec-15

Ciclosporin (Ikervis) is recommended as a possible

treatment for people with dry eye disease that has not

improved despite treatment with artificial tears.

Feb-16

TA370Bortezomib for previously untreated

mantle cell lymphomaDec-15

Bortezomib (Velcade) is recommended as a possible

treatment for adults with mantle cell lymphoma that has not

been treated before, if haematopoietic stem cell

transplantation is not suitable for them.

Feb-15

TA371

Trastuzumab emtansine for treating

HER2-positive, unresectable locally

advanced or metastatic breast cancer

after treatment with trastuzumab and a

taxan

Dec-15

Trastuzumab emtansine (Kadcyla) is not recommended.

This drug is for adults with advanced HER2-positive breast

cancer that has been treated before with trastuzumab and

a taxane (paclitaxel or docetaxel).

Feb-15






















TA374

Erlotinib and gefitinib for treating non-

small-cell lung cancer that has

progressed after prior chemotherapy

Dec-15

Erlotinib (Tarceva) is recommended as a possible

treatment for people with locally advanced or metastatic

non‑small‑cell lung cancer that has already been treated

with non-targeted chemotherapy because of delayed

confirmation of epidermal growth factor receptor tyrosine

kinase (EGFR‑TK) mutation status, if:

their cancer tests positive for the EGFR‑TK mutation or

it is not known if the cancer is EGFR‑TK mutation‑positive

because of problems with the test, and

- the cancer is very likely to be EGFR‑TK

mutation‑positive

- it responds to the first 2 cycles of treatment with

erlotinib.

Erlotinib is not recommended for treating locally advanced

or metastatic non‑small‑cell lung cancer that doesn’t test

positive for the EGFR‑TK mutation.

Gefitinib (Iressa) is not recommended for treating

non‑small‑cell lung cancer that has progressed after

chemotherapy.

Feb-15

TA372Apremilast for treating active psoriatic

arthritisDec-15

Apremilast (Otezla) is not recommended for adults with

active psoriatic arthritis when earlier treatment with disease-

modifying antirheumatic drugs (DMARDS) has not worked

well enough or isn’t suitable.

Feb-15

TA373

Abatacept, adalimumab, etanercept and

tocilizumab for treating juvenile idiopathic

arthritis

Dec-15

Abatacept (Orencia), adalimumab (Humira), etanercept

(Enbrel) and tocilizumab (RoActemra) are recommended as

possible treatments for people with polyarticular juvenile

idiopathic arthritis.

Adalimumab and etanercept are recommended as possible

treatments for people with enthesitis-related juvenile

idiopathic arthritis.

Etanercept is recommended as a possible treatment for

people with psoriatic juvenile idiopathic arthritis.

Feb-15













TA375

Adalimumab, etanercept, infliximab,

certolizumab pegol, golimumab,

tocilizumab and abatacept for rheumatoid

arthritis not previously treated with

DMARDs or after conventional DMARDs

only have failed

Jan-16

Adalimumab, etanercept, infliximab, certolizumab pegol,

golimumab,

tocilizumab and abatacept, all in combination with

methotrexate, are

recommended as options for treating rheumatoid arthritis,

only if:

disease is severe, that is, a disease activity score (DAS28)

greater than 5.1 and

disease has not responded to intensive therapy with a

combination of conventional

disease-modifying antirheumatic drugs (DMARDs) and

the companies provide certolizumab pegol, golimumab,

abatacept and tocilizumab as

agreed in their patient access schemes.

1.2 Adalimumab, etanercept, certolizumab pegol or

tocilizumab can be used as

monotherapy for people who cannot take methotrexate

because it is

contraindicated or because of intolerance, when the criteria

in section 1.1 are

met.

Mar-16

TA378

Ramucirumab for treating advanced

gastric cancer or gastro–oesophageal

junction adenocarcinoma previously

treated with chemotherapy

Jan-16

Ramucirumab alone or with paclitaxel is not recommended

within its marketing authorisation for advanced gastric

cancer or gastro–oesophageal junction adenocarcinoma

previously treated with chemotherapy.

1.2 People whose treatment with ramucirumab was started

within the NHS before this guidance was published should

be able to continue treatment until they and their clinician


Mar-16





TA376

Radium-223 dichloride for treating

hormone-relapsed prostate cancer with

bone metastases

Jan-16

Radium‑223 dichloride is recommended as an option for

treating adults with hormone‑relapsed prostate cancer,

symptomatic bone metastases and no known visceral

metastases, only if:

•they have had treatment with docetaxel, and

•the company provides radium‑223 dichloride with the

discount agreed in the patient access scheme.

Mar-16

TA380

Panobinostat for treating multiple

myeloma after at least 2 previous

treatments

Jan-16

Panobinostat in combination with bortezomib and

dexamethasone is recommended, within its marketing

authorisation, as an option for treating multiple myeloma,

that is, for 'adult patients with relapsed and/or refractory

multiple myeloma who have received at least 2 prior

regimens including bortezomib and an immunomodulatory

agent' when the company provides panobinostat with the

discount agreed in the patient access scheme.

Mar-16

TA381

Olaparib for maintenance treatment of

relapsed, platinum-sensitive, BRCA

mutation-positive ovarian, fallopian tube

and peritoneal cancer after response to

second-line or subsequent platinum-

based chemotherapy

Jan-16

Olaparib is recommended within its marketing authorisation

as an option for treating adults with relapsed, platinum

sensitive ovarian, fallopian tube or peritoneal cancer who

have BRCA1 or BRCA2 mutations and whose disease has

responded to platinum based chemotherapy only if:

•they have had 3 or more courses of platinum based

chemotherapy and

•the drug cost of olaparib for people who remain on

treatment after 15 months will be met by the company.

Mar-16





TA379Nintedanib for treating idiopathic

pulmonary fibrosisJan-16

Nintedanib is recommended as an option for treating

idiopathic pulmonary fibrosis, only if:

•the person has a forced vital capacity (FVC) between 50%

and 80% of predicted

•the company provides nintedanib with the discount agreed

in the patient access scheme and

•treatment is stopped if disease progresses (a confirmed

decline in percent predicted FVC of 10% or more) in any

12‑month period.

Mar-16

TA377

Enzalutamide for treating metastatic

hormone-relapsed prostate cancer before

chemotherapy is indicated

Jan-16

Enzalutamide is recommended, within its marketing

authorisation, as an option for treating metastatic

hormone‑relapsed prostate cancer:

•in people who have no or mild symptoms after androgen

deprivation therapy has failed, and before chemotherapy is

indicated

•and only when the company provides it with the discount

agreed in the patient access scheme

Mar-16


https://www.nice.org.uk/guidance/TA377/chapter/1-recommendations






TA382

Eltrombopag for treating severe aplastic

anaemia refractory to

immunosuppressive therapy (terminated

appraisal)

Jan-16

Novartis was invited to submit evidence for this single

technology appraisal for eltrombopag in September 2015.

The company did not make an evidence submission

because it was unable to develop robust clinical- or cost-

effectiveness analyses. The marketing authorisation for

eltrombopag for treating severe aplastic anaemia was

based on 1 small (n=43), non-comparative, single-centre

study. The primary endpoint (response rate) was measured

at 3 months, and the relationship between this and long-

term outcomes is unclear. All of these factors severely

limited the ability of the company to construct a robust case

for clinical or cost effectiveness.

NICE has therefore terminated this single technology

appraisal.

Mar-16









TA383

TNF-alpha inhibitors for ankylosing

spondylitis and non-radiographic axial

spondyloarthritis

Feb-16

Adalimumab, certolizumab pegol, etanercept, golimumab

and infliximab are recommended, within their marketing

authorisations, as options for treating severe active

ankylosing spondylitis in adults whose disease has

responded inadequately to, or who cannot tolerate,

non‑steroidal anti‑inflammatory drugs. Infliximab is

recommended only if treatment is started with the least

expensive infliximab product. People currently receiving

infliximab should be able to continue treatment with the

same infliximab product until they and their NHS clinician


1.2 Adalimumab, certolizumab pegol and etanercept are

recommended, within their marketing authorisations, as

options for treating severe non‑radiographic axial

spondyloarthritis in adults whose disease has responded

inadequately to, or who cannot tolerate, non‑steroidal

anti‑inflammatory drugs.

1.3 The choice of treatment should be made after

discussion between the clinician and the patient about the

advantages and disadvantages of the treatments available.

This may include considering associated conditions such

as extra‑articular manifestations. If more than 1 treatment

is suitable, the least expensive (taking into account

administration costs and patient access schemes) should

be chosen.

1.4 The response to adalimumab, certolizumab pegol,

etanercept, golimumab or infliximab treatment should be

assessed 12 weeks after the start of treatment. Treatment

should only be continued if there is clear evidence of

Mar-16


https://www.nice.org.uk/guidance/ta383/chapter/1-recommendations






TA384Nivolumab for treating advanced

(unresectable or metastatic) melanomaFeb-16

Nivolumab as monotherapy is recommended, within its

marketing authorisation, as an option for treating advanced

(unresectable or metastatic) melanoma in adults.

Mar-16







TA385

Ezetimibe for treating primary

heterozygous-familial and non-familial

hypercholesterolaemia

Feb-16

This guidance should be used with NICE's guidelines on

cardiovascular disease: risk assessment and reduction,

including lipid modification and familial

hypercholesterolaemia: identification and management.

1.2 Ezetimibe monotherapy is recommended as an option

for treating primary (heterozygous‑familial or non‑familial)

hypercholesterolaemia in adults in whom initial statin

therapy is contraindicated.

1.3 Ezetimibe monotherapy is recommended as an option

for treating primary (heterozygous‑familial or non‑familial)

hypercholesterolaemia in adults who cannot tolerate statin

therapy (as defined in section 1.6).

1.4 Ezetimibe, co‑administered with initial statin therapy, is

recommended as an option for treating primary

(heterozygous‑familial or non‑familial)

hypercholesterolaemia in adults who have started statin

therapy when:

•serum total or low‑density lipoprotein (LDL) cholesterol

concentration is not appropriately controlled (as defined in

section 1.7) either after appropriate dose titration of initial

statin therapy or because dose titration is limited by

intolerance to the initial statin therapy (as defined in section

1.6) and

•a change from initial statin therapy to an alternative statin

is being considered.

Mar-16





Notes (e.g. rationale, method of making available)

The JPG agreed to approve this medicine for use

at HUHFT provided it is used in accordance with

NICE TA 340 (BLUE – Hospital Only)







Adherence of local formulary to NICE





The JPG agreed not to approve this medicine for

use at the Homerton University Hospital,

Foundation Trust as the trust does not provide

this specialist service. The JPG recommends the

funding of this medicine to be prescribed or

initiated at specialist hospitals accredited to

provide this medicine, provided it is used in

accordance with NICE TA343. Hospital only

prescribing (formulary status BLUE)


use at the Homerton University Hospital







prescribing (Formulary status BLUE)



NICE TA 345 (BLUE – Hospital Only) Pathway to

be confirmed November 2015





The JPG agreed not to approve this medicine

for use at the Homerton University Hospital,

Foundation Trust as the trust does not

provide this specialist service. The JPG

recommends the funding of this medicine to

be prescribed or initiated at specialist

hospitals accredited to provide this medicine,

provided it is used in accordance with NICE

TA346. Hospital only prescribing (formulary

status BLUE)










status BLUE)


as currently NICE cannot recommend its use.














status BLUE)





The JPG agreed to approve this medicine for

use at HUHFT provided it is used in

accordance with NICE TA 341 (BLUE –

Hospital Only)

Pathway to be confirmed November 2015


as currently NICE cannot recommend its use








Hospital Only)

Pathway to be confirmed October 2015








Hospital Only)

Pathway to be confirmed November 2015






Hospital Only)








Hospital Only)












status BLUE)












status BLUE)







The JPG agreed not to approve this medicine as

currently NICE cannot recommend its use.


































NICE TA 367 (BLUE – Hospital Only). Pathway to

be confirmed with ELFT'




at HUHFT and City and Hackney CCG provided it

is used in accordance with NICE TA 369 (Amber

– specialist initiation). Information to be

disseminated in the GP newsletter and fact sheet

to be available on formulary website.





























NICE TA 373 (BLUE – Hospital Only) Pathway to

be confirmed April 2016













prescribing (formulary status BLUE). NHS

England funded.










status BLUE)








Hospital Only)














status BLUE)







accordance with NICE TA 385 Green Joint

formulary choice.


date of ta availability of medicine for nhs patients with ... · constipation (ta345) jul-15...

Documents